Poor survival after myocardial infarction in immune deficient NXG B2m mice is alleviated by transplantation of induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) formulated as spheres, but not single cells

Human iPSC-cardiomyocyte-aggregate cell therapy in non-human primates and correlation of heart recovery with contractile and electrophysiological cardiomyocyte properties

This study demonstrates the successful production and injection of human induced pluripotent stem cell cardiomyocyte aggregates into infarcted cynomolgus monkey hearts, resulting in substantial, structured human grafts three months after cell transplantation, and uncoupling of cardiomyocyte production from transplantat...

Sustained 10% Oxygen Promotes Atrial Rather Than Ventricular Specification During Human iPSC-Cardiomyocyte Differentiation

Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial

Primary efficacy analyses indicated that cell transplantation provided significantly greater improvements in 6-min walk distance, global myocardial perfusion and relative wall thickening and relative wall thickening compared with coronary artery bypass grafting alone.

Induced Pluripotent Stem Cells and 3D Bioprinting Strategies for Cardiac Regeneration After Myocardial Infarction

This study evaluates the role of iPSCs and different biofabrication methods, such as bioprinting, used to create ventricular constructs and cardiac patches that support injured regions of the heart post-MI.

Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets in a pacing-induced canine dilated cardiomyopathy model

IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidence that IHJ-301 could offer a promising therapeutic option for DCM.

Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery.

Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly...